PEOPLE - Alcon (US) makes appointment:
This article was originally published in Clinica
Fort Worth, Texas-based ophthalmic firm Alcon has appointed Cary Rayment as president and CEO. He is currently senior vice-president for Alcon US, and is also responsible for the company's global marketing and its operations in Japan. Mr Rayment succeeds Tim Sear, who has announced his retirement, effective October 1. Mr Sear will continue in his capacity as chairman and member of the board until the AGM in May 2005, when a new director and chairman will be elected.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.